Erasca reported expanded early-stage results for ERAS-0015, its experimental pan-RAS molecular glue, and preliminary monotherapy findings for ERAS-4001, a pan-KRAS inhibitor. The company said the ERAS-0015 data support moving faster toward a Phase 3 trial in first-line pancreatic cancer, which it now plans to start in the first half of 2027.
The results come from Phase 1 studies, where patient groups are small and treatment is still being evaluated. Erasca also described early combination findings, including safety results and some tumor responses, but efficacy data are not yet available for every combination.
ERAS-0015 monotherapy
- Across 122 patients treated at daily doses of 16–32 mg, ERAS-0015 was generally well tolerated, with mostly low-grade treatment-related side effects. The company reported no dose-limiting toxicities and few dose changes or interruptions.
- At 32 mg daily, among 54 patients, treatment-related side effects led to dose interruptions in 13% and dose reductions in 16.7%; none stopped treatment for those side effects. Median relative dose intensity was 100%.
-
In the reported safety table, rash was the most common treatment-related side effect: it occurred in 81.1% of patients across the 16–32 mg dose range, with 3.3% experiencing Grade 3 rash. Diarrhea occurred in 32%, with Grade 3 diarrhea in 0.8%. No Grade 4 or 5 cases of either were reported in the table.
-
Pancreatic cancer: Among 25 patients with KRAS G12X pancreatic ductal adenocarcinoma treated at 32 mg, the confirmed response rate was 44%. Most had received at least three prior lines of treatment, and 44% had KRAS G12R mutations.
- In a subgroup of 13 patients with KRAS G12D or G12V tumors, the confirmed response rate was 69%; 77% of this group had received at least three prior lines of treatment.
- The confirmed response rates were 63% among eight patients with G12D tumors and 80% among five with G12V tumors.
-
All 11 patients with confirmed responses, and six of 11 with stable disease, remained on treatment.
-
Non-small cell lung cancer: In patients previously treated with an immune checkpoint inhibitor and platinum-based chemotherapy, the confirmed response rate was 60% among five patients at 32 mg and 58% among 12 patients across the 16–32 mg dose range.
- At 32 mg, response rates were 60% among five patients with G12D tumors and 50% among four with G12V tumors.
-
All five patients with confirmed responses and all five with stable disease at 32 mg remained on treatment.
-
Biliary tract cancer: At 32 mg, three of four patients with KRAS G12X disease had confirmed responses; all three remained on treatment.
-
The monotherapy data cutoff was Sept. 1, 2026, with some responses confirmed after that date.
Combination studies and ERAS-4001
-
ERAS-0015 with gemcitabine and nab-paclitaxel: The combination was generally well tolerated, with no dose-limiting toxicities through the 16 mg ERAS-0015 dose level. Dose escalation was ongoing at 24 mg. Erasca said efficacy results were not yet available; it sees the early clinical findings as supporting further study in first-line pancreatic cancer.
-
ERAS-0015 with pembrolizumab: The combination was generally well tolerated, with no dose-limiting toxicities through 32 mg. The company reported multiple responses across solid tumor types in dose escalation. It said the data support further development in first-line non-small cell lung cancer, including a combination with carboplatin, pemetrexed and pembrolizumab that began in the fourth quarter of 2026.
-
ERAS-0015 with panitumumab: At 16 mg, the combination was generally well tolerated. In patients with KRAS G12X colorectal cancer, the company reported two ongoing confirmed partial responses in patients treated at 24 mg who later reduced their dose to 16 mg, and one unconfirmed partial response among four patients treated at 16 mg. Dose exploration continues, with a dose selection planned for 2027.
-
ERAS-4001: Preliminary Phase 1 monotherapy results showed a favorable safety and tolerability profile, predominantly low-grade side effects, and no treatment-related side effects leading to discontinuation. Early pharmacokinetic results supported continued dose escalation. Erasca described preliminary antitumor activity but did not provide response rates or patient counts in the announcement.
-
Erasca is evaluating ERAS-4001 as a potential partner for ERAS-0015. The company cited nonclinical results showing that the two drugs target active and inactive forms of KRAS and had synergistic activity in KRAS G12X-driven models. Initial ERAS-4001 data were current as of Nov. 9, 2026; the combination safety update had an Oct. 14 cutoff.
What changes
The clearest near-term development is Erasca’s plan to accelerate a Phase 3 trial of ERAS-0015 in first-line pancreatic cancer to the first half of 2027. The Phase 1 response rates provide early clinical evidence across several KRAS-mutant cancers, but many of the reported subgroups are small. Combination programs remain at an earlier stage: some have encouraging safety or response observations, while the gemcitabine/nab-paclitaxel combination has no efficacy data yet.
